Protein Kinase C-alpha Activity Modulates Transepithelial Permeability and Cell Junctions in the LLC-PK1 Epithelial Cell Line*

(Received for publication, February 18, 1997, and in revised form, March 26, 1997)

Dan Rosson Dagger §, Thomas G. O'Brien Dagger , Jennifer A. Kampherstein Dagger , Zoltan Szallasi par , Krisztina Bogi , Peter M. Blumberg and James M. Mullin Dagger

From the Dagger  Lankenau Medical Research Center, Wynnewood, Pennsylvania 19096-3411 and the  Laboratory of Cellular Carcinogenesis and Tumor Promotion, NCI, National Institutes of Health, Bethesda, Maryland 20892-4255

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Modulation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) disrupts the cell-cell junctions of the epithelial cell line LLC-PK1. To examine the role of specific PKC isoforms in this process we have created modified LLC-PK1 subclones that express wild-type and dominant negative versions of PKC-alpha under control of the tetracycline-responsive expression system. Overexpression of wild-type PKC-alpha rendered the cells more sensitive to the effects of TPA on transepithelial permeability as measured by loss of transepithelial resistance across the cell sheet. Conversely, expression of a dominant negative PKC-alpha rendered the cells more resistant to the effects of TPA as measured both by loss of transepithelial resistance as well as cell scattering. The properties of both subclones could be modulated by the addition of tetracycline, which suppressed the effect of the exogenous genes. These results indicate that the alpha  isoform of PKC is at least one of the isoforms that regulate tight junctions and other cell-cell junctions of LLC-PK1 epithelia.


INTRODUCTION

Epithelial cells cover almost all internal and external body surfaces. All types of epithelia are polarized with apical and basolateral surfaces that have different membrane proteins and thereby different functions. The cells thus compartmentalize the tissues of which they are a part. The cells exist in sheets in which individual cells are interconnected by various types of cell-cell junctions, the regulation of which is at play during development, wound healing, and pathological processes such as cancer or chronic inflammation. Therefore, the control of cell-cell junctions and their disruption and reformation is of interest in several fields.

The LLC-PK1 cell line (1) offers an advantageous model system for studying this process. The cell line grows subconfluently as islands of adherent cells. Upon reaching confluence, it forms a differentiated epithelial monolayer with functionally intact tight junctions. Treatment of subconfluent cultures with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)1 causes a breakdown of the cell junctions resulting in a more scattered growth pattern. Acute exposure of LLC-PK1 confluent cell sheets to TPA causes a rapid decrease in the transepithelial resistance (TER) to less than 15% of its initial value (2) because of its effect on one type of cell junction known as tight junctions.

We have been interested in the molecular events in this process and have concentrated much of our efforts on protein kinase C (PKC), the molecular target of TPA. PKC has been shown to be one of the process's key components. Treatment of LLC-PK1 cells with the PKC inhibitor GF109203X inhibits the effects of TPA (3). PKC mediates calcium-induced tight junction assembly (4), and its inhibition prevents the proper distribution of tight junction-associated proteins such as ZO-1 and cingulin (5). One of the issues in PKC-mediated cell junction regulation is which specific isoform(s) is at play. PKC is not a single protein, as the name implies, but a family of proteins with at least 11 different members (6). Although each member or isoform is encoded by a separate gene, they all consist of conserved regulatory and catalytic regions. The isoforms can be divided into four classes based on regulatory properties. The first class, the conventional PKCs alpha , beta , and gamma , is regulated by calcium. The second, nonconventional or novel class, is made up of PKCs delta , epsilon , eta , and theta , which are not regulated by calcium. The third class, the atypical PKCs zeta  and (lambda /iota ), is not regulated by calcium or TPA. A recently discovered isoform, PKC-µ, represents a fourth class, which is topologically related to the PKC family but possesses a kinase domain more related to calcium/calmodulin-dependent kinases. The complexity of the PKC family and the differential expression of the isoforms suggest that the members serve distinct roles in signal transduction processes. To examine this issue, as it relates to PKC-mediated cell junction regulation in LLC-PK1 epithelial cells, we have begun to modulate the activities of individual isoforms by exogenously expressing wild type and dominant negative versions of the genes in an inducible expression system. LLC-PK1 cells express the alpha , delta , epsilon , and zeta  isoforms of PKC, and, in this study, we report that alteration of the activity of the alpha  isoform of PKC modulates the integrity of cell-cell junctions as measured by sensitivity to TPA.


EXPERIMENTAL PROCEDURES

Construction of Expression Vectors

Expression vectors comprising the tetracycline-responsive expression system described by Gossen and Bujard (7) were used to express both wild-type and dominant negative versions of PKC-alpha . cDNA encoding the entire reading frame of wild-type PKC-alpha was excised from its original vector (8) by digestion with EcoRI and recloned into the EcoRI site of the tetracycline-responsive vector pUHD10-3 creating pUHD10-3alpha .

A dominant negative version of the gene was created by in vitro mutagenesis replacing the conserved lysine in the ATP binding domain in position 368 with an alanine. The XcmI-BsiWI fragment spanning the Lys right-arrow Ala mutation was then excised from its expression vector to replace the analogous fragment in pUHD10-3alpha vector creating pUHD10-3alpha DN.

Cell Cultures and Transfections

LLC-PK1 cells were maintained in minimum essential medium alpha  supplemented with 10% fetal bovine serum (HyClone Laboratories). When tetracycline was present, its concentration was 1 µg/ml. For transfection, cells were harvested by trypsinization, washed, and 5 × 106 cells were resuspended in 0.8 ml of phosphate-buffered saline in an electroporation cuvette (0.4 cm). 20 µg of pUHD15-1, which encodes the bacterial transactivator tTA, along with 5 µg of a plasmid conferring resistance to hygromycin, were added to the suspension. This was subjected to one pulse (300 V; 250 microfarads) in a Bio-Rad electroporator. Cells were then plated onto three 10-cm tissue culture plates, incubated for 1 day, then adjusted to 400 µg/ml hygromycin. 2-4 weeks later, drug-resistant clones were isolated, expanded, and analyzed by transient transfection for tetracycline-responsive expression of a luciferase reporter gene cloned into the pUHD10-3 expression vector. One of the resulting subclones, LLC-PK1tTA, was selected for subsequent constructions, which were to stably transfect the PKC-alpha expression vectors described above. This was performed by the same electroporation procedure utilizing 5 µg of pSVzeo (Invitrogen) and 1 mg/ml zeocin for selection. Expression of wild-type and dominant negative PKC-alpha was assessed by Western analysis.

Western Analysis

Cells were harvested by trypsinization followed by centrifugation. Cell pellets were then lysed in Tris-Cl buffer containing 0.1% sodium dodecyl sulfate and proteinase inhibitors. DNA was sheared to reduce viscosity, and the protein concentration was determined with Bio-Rad protein assay dye reagent. 50 µg of total protein was mixed with an equal volume of 2 × sample buffer (0.125 M Tris-Cl, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol, 10% 2-mercaptoethanol, 0.002% bromphenol blue). Samples were heated in a boiling water bath for 5 min and then loaded onto a denaturing 6% polyacrylamide electrophoresis gel.

After separation, proteins were electrophoretically transferred to a nitrocellulose membrane. The filters were first treated with Tris-buffered saline (50 mM Tris-Cl, pH 7.5, 0.15 M NaCl) with 0.05% Tween 20 (TBST) containing 3% nonfat milk. This was followed by hybridization in 5 ml of TBST with 1% bovine serum albumin and 1 µg of anti-PKC-alpha antibody (Upstate Biotechnology, Inc.) for 5 h at room temperature. The blots were subsequently washed in TBST and then incubated with anti-mouse peroxidase-conjugated antibody (Amersham) for 1 h. After washing in TBST, the blots were developed using the enhanced chemiluminescence Western blotting system (Amersham).

TER Measurements

Electrical equipment and protocols for electrical measurement have been described before (9). Briefly, 1 × 106 cells were seeded onto Falcon 3102 filter rings (4.2 cm2). On day 4, after which electrical resistance across the cell sheet had stabilized, cells were refed with fresh media, incubated for 1-2 h, and then their initial TER was measured. Cell sheets were then refed with media containing 1.0 × 10-8 M TPA, and electrical resistance across the cell sheet was determined through the course of resistance decreases. Measurements were done in triplicate, and all results are representative of at least three experiments.

TPA-induced Cell Scattering

For assessment of cell scattering 3 × 103 cells were seeded in 24-well plates in 1 ml of medium containing 10-8 M TPA. Growth patterns were followed by light microscopy and photographed 3 days after seeding.


RESULTS

Since we have noted previously that TPA treatment of LLC-PK1 cells is associated with a translocation of PKC-alpha from the cytosolic fraction of the cells to the membrane fraction (9), we decided to modulate the activity of PKC-alpha by exogenous expression of the gene. Because randomly isolated sublines can vary from the parental in any given property, there is consequent difficulty in ascribing any phenotypic change to the expression of an exogenous gene. We chose to avoid the problems of clonal variation by utilizing the tetracycline-responsive expression system of Gossen and Bujard (7) to overexpress PKC-alpha . In the first step, we cotransfected into LLC-PK1 cells a plasmid expressing tTA and a plasmid conferring hygromycin resistance. After screening drug-resistant clones for tetracycline-repressible expression of tTA, we selected a subline, LLC-PK1tTA, for additional experiments. Next, pUHD10-3 PKC-alpha was transfected into LLC-PK1tTA using pSVzeo (Invitrogen) as a coselectable marker. 20 drug-resistant clones were analyzed for expression of PKC-alpha , and one was found to have elevated levels. Fig. 1 shows Western analysis of extracts of cells cultured with and without tetracycline, expressing exogenous PKC-alpha . Parental cells exhibited a single protein of approximately 75 kDa. LLC-PK1alpha cells grown in the absence of tetracycline exhibited PKC-alpha levels that were 10-20 times higher. The same subline grown in the presence of tetracycline showed levels that were almost equal to levels in the parental LLC-PK1 tTA line. Phenotypically, the cells resemble the parental line, growing as islands of coherent cells. Upon reaching confluence, both the transfectant and the parental line remain a single layer and differentiate into a polar epithelial-like cell sheet with apical and basolateral surfaces. Both lines form dome-like or cystic structures as a result of the vectorial transepithelial transport and the tight junctions of the cell sheet. However, as seen in Fig. 2, not only do domes collapse when treated with TPA, but the transfected cells rapidly round up and begin to detach from the dish. When expression of the exogenous PKC-alpha was down-regulated by the addition of tetracycline, the normal dome collapse occurred on TPA treatment but not the cell rounding and detaching. The disruption of tight junctions was assessed quantitatively in measurements of TER decreases on TPA treatment. As seen in Fig. 3, cells overexpressing PKC-alpha showed a more rapid response to all concentrations of TPA tested compared with wild type LLC-PK1. However, when these cells were grown in the presence of tetracycline, TER decreases matched that of the parental line. The presence of tetracycline had no effect on TER decreases in wild-type LLC-PK1 (data not shown).


Fig. 1. Western analysis of LLC-PK1alpha . Whole cell extracts were prepared, quantitated, and subjected to Western gel analysis as described under "Experimental Procedures." The sources of the protein extracts are as follows: lane 1, LLC-PK1tTA; lane 2, LLC-PK1alpha grown in the absence of tetracycline; lane 3, LLC-PK1alpha grown in the presence of tetracycline.
[View Larger Version of this Image (39K GIF file)]


Fig. 2. Phase-contrast micrographs of LLC-PK1alpha and its parental line before and after TPA treatment. Panels A and B are confluent cell sheets of LLC-PK1alpha and the parental LLC-PK1tTA, respectively. Both show morphologically identical single layered cell sheets with abundant dome formation characteristic of differentiated epithelial cell sheets. Panels C and D are LLC-PK1alpha and LLC-PK1tTA, respectively, 1 h after adjustment of the media to 10-7 M TPA.
[View Larger Version of this Image (70K GIF file)]


Fig. 3. TER as a function of duration of exposure to TPA. Plotted is the percentage of initial resistance (approximately 300 Omega ·cm2) versus time of exposure to TPA. Panel A, which shows TER decreases of LLC-PK1tTA at various TPA concentrations, and panel B, which shows TER decreases of LLC-PK1alpha (-tetracycline) at various TPA concentrations, together demonstrate the enhanced sensitivity at several TPA concentrations of LLC-PK1alpha compared with the parental line. TPA concentrations in panels A and B are as follows (in Mm): black-square, 10-11; black-triangle, 10-10; bullet , 10-9; square , 10-8; open circle , 10-7. Panel C shows a comparison of TER decreases in LLC-PK1alpha in the presence and absence of tetracycline along with that of the parental line at a TPA concentration of 10-8. Cell lines are represented as follows: black-square, LLC-PK1tTA; bullet , LLC-PK1alpha (+tetracycline); black-triangle, LLC-PK1alpha (-tetracycline). Points were measured in triplicate, and error bars, which represent S.D., are shown when greater than 1%.
[View Larger Version of this Image (10K GIF file)]

To generate a subline of LLC-PK1 cells expressing an inducible dominant negative version of PKC-alpha , we transfected pUHD10-3alpha DN into LLC-PK1tTA by the same procedure as described above. Fig. 4 shows the Western analysis of four clones that were isolated. Each showed an exogenous protein running 4-5 kDa below the endogenous PKC-alpha . In all four clones, the exogenous protein was down-regulated significantly by tetracycline. PKC is first synthesized as an inactive unphosphorylated polypeptide. It is first phosphorylated by an unknown PKC kinase and then undergoes two autophosphorylations to generate the active species (10). The kinase-dead dominant negative protein is obligatorily unable to autophosphorylate and therefore displayed a faster electrophoretic migration compared with the endogenous protein.


Fig. 4. Western analysis of LLC-PK1alpha DN. Whole cell extracts were prepared, quantitated, and subjected to Western analysis as described under "Experimental Procedures." The sources of the protein extracts are as follows: lanes 1 and 2, LLC-PK1tTA; lanes 3 and 4, LLC-PK1alpha DN clone 1; lanes 5 and 6, LLC-PK1alpha DN clone 2; lanes 7 and 8, LLC-PK1alpha DN clone 3; lanes 9 and 10, LLC-PK1alpha DN clone 4. In odd numbered lanes, the extracts were prepared from cells grown in the absence of tetracycline; even numbered lanes are prepared from cells grown in the presence of tetracycline. wt, wild-type.
[View Larger Version of this Image (23K GIF file)]

Physiologically, the effect of PKC-alpha DN was the opposite of its wild-type counterpart. LLC-PK1alpha DN cells grown in the absence of tetracycline showed a much slower response to 10-8 M TPA than did parental counterparts. As seen in Fig. 5, at 1 h of treatment, TERs of LLC-PK1alpha DN were 80% of their initial value, whereas the parental cells had decreased to 25%. The degree of tetracycline responsiveness of the system is also seen in electrical measurements with LLC-PK1alpha DN cells grown in the presence of tetracycline which showed responses to TPA nearly identical to those of parental LLC-PK1tTA.


Fig. 5. TER of LLC-PK1alpha DN as a function of duration of exposure to 10-8 M TPA. Cell lines are represented as follows: black-square, LLC-PK1tTA; black-triangle, LLC-PK1alpha DN (-tetracycline); bullet , LLC-PK1alpha DN (+tetracycline). Points were measured in triplicate; error bars, which represent S.D., are shown when greater than 1%.
[View Larger Version of this Image (11K GIF file)]

We next assessed the effects of PKC-alpha DN expression on growth patterns of the line. LLC-PK1, like most epithelial lines, grow as islands of coherent cells. Treatment of subconfluent cultures with TPA disrupts the cell junctions that produce this compact architecture. The result is a more fibroblastic growth pattern with individual cells migrating away from the island and a more scattered appearance. Fig. 6 shows the results of TPA treatment of LLC-PK1alpha DN cells grown in the presence and absence of tetracycline. With expression of PKC-alpha DN turned off, treatment of cells with TPA induced a scattered growth pattern identical to that of wild type cells treated with TPA (panel B). However, with the expression of PKC-alpha DN turned on, TPA-induced cell scattering was completely inhibited; that is, growth patterns were identical to either wild type LLC-PK1 or LLC-PK1alpha DN in the absence of TPA.


Fig. 6. Phase-contrast micrographs of LLC-PK1alpha DN. Cells were plated in the presence of TPA as described under "Experimental Procedures." Panel A shows cells grown in the absence of tetracycline. Panel B shows cells grown in the presence of tetracycline.
[View Larger Version of this Image (107K GIF file)]


DISCUSSION

Protein phosphorylation is the primary mechanism for controlling diverse and complex cellular processes that affect structure, growth, and differentiation. Among the many kinases that are at play in these events is PKC, which often plays a pivotal role in the signal transduction process. Additionally, because PKC is the major receptor for tumor-promoting phorbol esters such as TPA, the long history of tumor promotion research has led to a wealth of information indicating that the modulation of PKC activity is a key step in tumorigenesis as well. The development of an invasive tumor involves a disruption of normal cell-cell junctions that serve to maintain tissue architecture. Additionally, more recent studies have indicated that the mechanism of action of many growth factor receptors involves activation of PKC. This occurs via phospholipase C, which produces diacylglycerol, which binds to and activates the enzyme in the same manner as TPA. The receptor for scatter factor or hepatocyte growth factor, c-Met, is an example of such a receptor, indicating that PKC plays a role in producing a response to this cytokine.

Soon following the initial discovery of PKC, the activity was found to consist of more than one species. With the advent of techniques in molecular biology, the family of isoforms has since grown to include 11 members (6). Differences in tissue distribution, subcellular distribution, and substrate specificity suggest that there is a divergence of function among the isoforms. However, despite the abundance of PKC research, little information is available on the roles of individual isoforms. Since inhibitors of the enzyme are not specific for individual isoforms, we and others have begun to address this issue by the use of exogenous expression studies. This technique, which utilizes both wild-type and dominant negative versions of the gene to modulate the activity of specific individual isoforms, is beginning to indicate which isoforms are involved in particular processes.

We have begun examining the role of the alpha  isoform in the disruption of cell junctions. Calcium plays an established role in the maintenance of various cell junctions including tight junctions (4, 11), and PCKalpha is the major calcium-dependent isoform expressed in LLC-PK1 cells. Its activity is essential for v-ras transformation of keratinocytes (12), and we have previously noted that, upon TPA treatment, PKC-alpha translocates from the cytosolic to the membrane fraction. This occurs in a time-dependent manner, which correlates with increased leakiness of tight junctions. Furthermore, in cells chronically treated with TPA, which form uneven cell sheets of single and multilayered areas, PKC-alpha stays up-regulated in areas in which there is multilayering, which also is where tight junctions are most leaky (9). Ellis et al. (13) report that an LLC-PK1 subline that decreases and then rapidly recovers its TER in response to TPA also rapidly down-regulates its PKC activity, whereas a subline whose TER does not recover in the presence of TPA does not down-regulate its PKC.

Our results show that a direct correlation exists between activity levels of PKC-alpha and the sensitivity of LLC-PK1 cell junctions to TPA; that is, up-regulation by expression of exogenous wild-type PKC-alpha enhances sensitivity, and down-regulation by expression of the dominant negative form decreases sensitivity. Although in vitro studies of PKC show a lack of specificity toward certain substrates, several literature studies have reported that the technique of exogenous expression of individual members of the PKC family produces results specific for individual isoforms. For example, Li et al. (14) expressed six different isoforms of PKC in 32D cells and reported that only the expression of the delta  isoform rendered the cells sensitive to TPA-induced differentiation. In experiments with NIH 3T3 cells, the delta  isoform inhibited cell growth, whereas the epsilon  isoform rendered the cells tumorigenic (15). Similarly, Baier-Bitterlich et al. (16) reported that only the theta  isoform was competent in stimulation of AP-1 activity in T-lymphocytes. This specificity might be explained in part by the fact that isoforms are compartmentalized differently in cells, conferring specificity to given substrates by spatial accessibility. For example, PKC-delta has been localized to the cytoskeleton of HL-60 cells (17), and PKC-zeta has been localized by immmunoelectron microscopy in Madin-Darby canine kidney epithelia to the region of the zonula occludens and/or zonula adherens (18). Transfection of endothelia with antisense PKC-beta blocked the phorbol ester-induced increase in tight function permeability normally seen in these cell sheets (19). Similarly, overexpression of PKC-beta yields an endothelial cell sheet with a dramatically increased effect of phorbol ester on tight junction permeability (20). We have begun to examine other isoforms of PKC in terms of the effect they have on regulating cell junctions in LLC-PK1 and are finding similar results.

Our work represents a significant step toward identifying the relevant isoforms of PKC in regulating cell junctions. More work is necessary to identify the mechanism of this regulation. Many putative targets of PKC have been identified which are associated with cell junctions. Among these are c-Raf (21), vinculin (22), talin (22), MARCKS (23), glycogen synthase kinase-3 (24) and focal adhesion kinase (25). PKC-mediated modulation of any one of these might conceivably play a role in reorganizing cytoskeletal structures during TPA-induced cell migration and disruption of cell junctions.


FOOTNOTES

*   This work was supported by National Institutes of Health Grants CA36353 (to T. G. O.) and CA48121 (to J. M. M.) from the NCI.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Lankenau Medical Research Center, 100 Lancaster Ave., Wynnewood, PA 19096-3411. Tel.: 610-645-3420; Fax: 610-645-2205.
par    Present address: Dept. of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.
1   The abbreviations used are: TPA, 12-O-tetradecanoylphorbol-13-acetate; TER, transepithelial resistance; PKC, protein kinase C; tTA, tetracycline-responsive transactivating protein.

ACKNOWLEDGEMENTS

We thank Drs. Gossen and Bujard for plasmids making up the tetracycline-responsive expression system and Dr. Shigeo Ohno for the cDNA for wild type PKC-alpha .


REFERENCES

  1. Hull, R. N., Cherry, W. R., and Weaver, G. W. (1976) In Vitro 12, 670-677 [Medline] [Order article via Infotrieve]
  2. Mullin, J. M., and O'Brien, T. G. (1986) Am. J. Physiol. 251, C597-C602 [Abstract/Free Full Text]
  3. Marano, C. W., Laughlin, K. V., Russo, L. M., and Mullin, J. M. (1995) Biochem. Biophys. Res. Commun. 209, 669-676 [CrossRef][Medline] [Order article via Infotrieve]
  4. Balda, M. S., Gonzalez-Mariscal, L., Matter, K., Cereijido, M., and Anderson, J. M. (1993) J. Cell Biol. 123, 293-302 [Abstract]
  5. Nigam, S. K., Denisenko, N., Rodriguez-Boulan, E., and Citi, S. (1991) Biochem. Biophys. Res. Commun. 181, 548-553 [Medline] [Order article via Infotrieve]
  6. Dekker, L. V., and Parker, P. J. (1994) Trends Biochem. Sci. 19, 51-98 [Medline] [Order article via Infotrieve]
  7. Gossen, M., and Bujard, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5547-5551 [Abstract]
  8. Ohno, S., Akita, Y., Konno, Y., Imajoh, S., and Suzuki, K. (1988) Cell 53, 731-741 [Medline] [Order article via Infotrieve]
  9. Mullin, J. M., Peralta Soler, A., Laughlin, K. V., Kampherstein, J. A., Russo, L. M., Saladik, D. T., George, K., Shurina, R. D., and O'Brien, T. G. (1996) Exp. Cell Res. 227, 12-22 [CrossRef][Medline] [Order article via Infotrieve]
  10. Newton, A. C. (1995) J. Biol. Chem. 270, 28495-28498 [Free Full Text]
  11. Jovov, B., Lewis, S. A., Crowe, W. E., Berg, J. R., and Wills, N. K. (1994) Am. J. Physiol. 266, F775-F784 [Abstract/Free Full Text]
  12. Dlugosz, A. A., Cheng, C., Williams, E. K., Dharia, A. G., Denning, M. F., and Yuspa, S. H. (1994) Cancer Res. 54, 6413-6420 [Abstract]
  13. Ellis, B., Schneeberger, E. E., and Rabito, C. A. (1992) Am. J. Physiol. 263, F293-F300 [Abstract/Free Full Text]
  14. Li, W., Mischak, H., Yu, J.-C., Wang, L.-M., Mushinski, J. F., Heidaran, M. A., and Pierce, J. H. (1994) J. Biol. Chem. 269, 2349-2352 [Abstract/Free Full Text]
  15. Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaechtle, C., Kazanietz, M. G., Blumberg, P. M., Pierce, J. H., and Mushinski, J. F. (1993) J. Biol. Chem. 268, 6090-6096 [Abstract/Free Full Text]
  16. Baier-Bitterlich, G., Überall, F., Bauer, B., Fresser, F., Wachter, H., Grunicke, H., Utermann, G., Altman, A., and Baier, G. (1996) Mol. Cell. Biol. 16, 1842-1850 [Abstract]
  17. Owen, P. J., Johnson, G. D., and Lord, T. M. (1996) Exp. Cell Res. 225, 366-373 [CrossRef][Medline] [Order article via Infotrieve]
  18. Dodane, V., and Kachar, B. (1996) J. Membr. Biol. 149, 199-209 [CrossRef][Medline] [Order article via Infotrieve]
  19. Lum, H., and Malik, A. B. (1996) Am. J. Physiol. 267, L223-L241
  20. Nagpala, P. G., Malik, A. B., Vuong, P. T., and Lum, H. (1996) J. Cell. Physiol. 166, 249-255 [CrossRef][Medline] [Order article via Infotrieve]
  21. Kolch, W., Heldecker, G., Kochs, G., Hummel, R., Vahldl, H., Mischak, H., Finkenzeller, G., Marmé, D., and Rapp, U. (1993) Nature 364, 249-252 [CrossRef][Medline] [Order article via Infotrieve]
  22. Lichtfield, D. W., and Ball, E. H. (1986) Biochem. Biophys. Res. Commun. 134, 1276-1283 [Medline] [Order article via Infotrieve]
  23. Aderem, A. (1992) Cell 71, 713-716 [Medline] [Order article via Infotrieve]
  24. Goode, N., Hughes, K., Woodgett, J. R., and Parker, P. J. (1992) J. Biol. Chem. 267, 16878-16882 [Abstract/Free Full Text]
  25. Zachary, I., and Rozengurt, E. (1992) Cell 71, 891-894 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.